Wolfson Institute of Preventive Medicine: To determine the value of preventive angioplasty (a procedure in which fine balloons are positioned and expanded within coronary arteries) to dilate all identified significantly na
Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.
- Organisation
- Wolfson Institute of Preventive Medicine
- Source reference
- DARS-NIC-148066-2B6LS-v0.0
- Jurisdiction
- England
- Licence
- Open Government Licence v3.0, subject to NHS England terms and exclusions
To determine the value of preventive angioplasty (a procedure in which fine balloons are positioned and expanded within coronary arteries) to dilate all identified significantly narrowed coronary arteries among patients having therapeutic angioplasty to treat a myocardial infarction; ie angioplasty limited to unblocking the artery causing the myocardial infarction. The primary aim is to determine whether preventive angioplasty undertaken at the time of treating the artery responsible for the myocardial infarction reduces the incidence of the combined endpoint of coronary death, non−fatal myoca
- Register reference
- DARS-NIC-148066-2B6LS-v0.0
- Agreement period
- not published to no end date published
- For commercial purposes (as marked in the register)
- Not stated
- Release files listed by NHS England
- 2
Data approved
- MRIS - Cause of Death Report
- MRIS - Cohort Event Notification Report
Objective, as published
To determine the value of preventive angioplasty (a procedure in which fine balloons are positioned and expanded within coronary arteries) to dilate all identified significantly narrowed coronary arteries among patients having therapeutic angioplasty to treat a myocardial infarction; ie angioplasty limited to unblocking the artery causing the myocardial infarction. The primary aim is to determine whether preventive angioplasty undertaken at the time of treating the artery responsible for the myocardial infarction reduces the incidence of the combined endpoint of coronary death, non−fatal myocardial infarction and refractory angina. The secondary aims are: 1. To determine and quantify the safety of preventive angioplasty among patients undergoing therapeutic angioplasty for an acute myocardial infarction. 2. To undertake an economic evaluation comparing the cost to the NHS of preventive PCI. 3. To undertake a quality of life assessment in patients randomised to each treatment strategy.
Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/http://content.digital.nhs.uk/media/22305/Data-Release-Register-April-to-August-2016/xls/Data_Release_Register__April_-_August_2016.xlsx. Captured 2026-10-30.
Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.